<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39349765</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1745-7254</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Acta pharmacologica Sinica</Title><ISOAbbreviation>Acta Pharmacol Sin</ISOAbbreviation></Journal><ArticleTitle><sup>19</sup>F qNMR based pharmacokinetics, metabolism and mass balance studies of SARS-CoV-2-3CL protease inhibitor simnotrelvir (SIM0417) in humans.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41401-024-01393-7</ELocationID><Abstract><AbstractText>Simnotrelvir (SIM0417), an inhibitor of the 3CL protease of SARS-CoV-2, has been identified as a CYP3A sensitive substrate. This study investigated the pharmacokinetics, metabolism, and mass balance of simnotrelvir following a single oral dose of 750 mg in six healthy Chinese male subjects, co-administered with four doses of 100 mg ritonavir. Analysis using <sup>19</sup>F qNMR combined with LC-MS/MS showed that the parent drug M0 constituted over 90% of the drug-related components in plasma. Of the administered dose, 55.4% (54.3% of M0) was recovered in urine, while 36.7% (4.57% of M0) was excreted in feces. UPLC/Q-TOF MS was used to identify metabolites in human plasma, urine and feces. Notably, oxidative metabolites catalyzed by CYP3A were scarcely detected in these matrixes. The amide hydrolyzed metabolite M9 and the cyano hydrolyzed metabolite M10 were recognized as the predominant metabolites, with the main excretion being through feces (19.0% and 12.7% of the administered dose, respectively). In vitro experiments indicated that M10 is primarily formed in the duodenum and jejunum, with further metabolism to M9 by microbiota in the large intestine. Overall, the co-administration of simnotrelvir with ritonavir led to predominant metabolism by intestinal enzymes or microbiota, resulting in hydrolyzed metabolites. These findings highlight the critical role of intestinal metabolism in the pharmacokinetics of simnotrelvir and emphasize the need to consider interactions with antibiotics and individual differences of intestinal microbiota.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Ze-Yu</ForeName><Initials>ZY</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ren</LastName><ForeName>Yong-Mei</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Shu-Wei</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Nai-Xia</ForeName><Initials>NX</Initials><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, 100049, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Meng-Xiao</ForeName><Initials>MX</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, 210042, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Simcere Zaiming Pharmaceutical Co. Ltd., Nanjing, 210042, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Zi-Jia</ForeName><Initials>ZJ</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, 210042, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jiangsu Simcere Pharmaceutical Co., Ltd, Nanjing, 210042, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Shan-Sen</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, 210042, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jiangsu Simcere Pharmaceutical Co., Ltd, Nanjing, 210042, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, 210042, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Simcere Zaiming Pharmaceutical Co. Ltd., Nanjing, 210042, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goh</LastName><ForeName>Aik Han</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, 210042, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jiangsu Simcere Pharmaceutical Co., Ltd, Nanjing, 210042, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiao-Yan</ForeName><Initials>XY</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. xychen@simm.ac.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, 100049, China. xychen@simm.ac.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Pharmacol Sin</MedlineTA><NlmUniqueID>100956087</NlmUniqueID><ISSNLinking>1671-4083</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">19F qNMR</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">mass balance.</Keyword><Keyword MajorTopicYN="N">metabolism</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword><Keyword MajorTopicYN="N">simnotrelvir</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39349765</ArticleId><ArticleId IdType="doi">10.1038/s41401-024-01393-7</ArticleId><ArticleId IdType="pii">10.1038/s41401-024-01393-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization [homepage on the Internet].data.who.int, WHO Coronavirus (COVID-19) dashboard &gt; Cases [Dashboard]. [updated 2024 May 5; cited 2024 May 23] Available from: https://data.who.int/dashboards/covid19/cases?n=c .</Citation></Reference><Reference><Citation>Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId><ArticleId IdType="pmc">7092803</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId><ArticleId IdType="pmc">7095418</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289–93.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2223-y</ArticleId><ArticleId IdType="pubmed">32272481</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao B, Wang Y, Lu HZ, Huang CL, Yang YM, Shang LH, et al. Oral simnotrelvir for adult patients with mild-to-moderate Covid-19. N Engl J Med. 2024;390:230–41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2301425</ArticleId><ArticleId IdType="pubmed">38231624</ArticleId><ArticleId IdType="pmc">11156186</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang FX, Xiao W, Tang YM, Cao ML, Shu D, Asakawa T, et al. Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo- controlled, phase 1b trial. Lancet Reg Health West Pac 2023;38:100835.</Citation></Reference><Reference><Citation>Jiang X, Su H, Shang W, Zhou F, Zhang Y, Zhao W, et al. Structure-based development and preclinical evaluation of the SARS-CoV-23C-like protease inhibitor simnotrelvir. Nat Commun. 2023;14:6463.</Citation></Reference><Reference><Citation>Yang XM, Yang Y, Yao BF, Ye PP, Xu Y, Peng SP, et al. A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects. Eur J Pharm Sci. 2023;191:106598.</Citation></Reference><Reference><Citation>Ramamoorthy A, Bende G, Chow ECY, Dimova H, Hartman N, Jean D, et al. Human radiolabeled mass balance studies supporting the FDA approval of new drugs. Clin Transl Sci. 2022;15:2567–75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.13403</ArticleId><ArticleId IdType="pubmed">36066467</ArticleId><ArticleId IdType="pmc">9652429</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson D, Garnier M, Luneau A, James AD, Walles M. 19)F-NMR-based determination of the absorption, metabolism and excretion of the oral phosphatidylinositol-3-kinase (PI3K) delta inhibitor leniolisib (CDZ173) in healthy volunteers. Xenobiotica. 2019;49:953–60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00498254.2018.1523488</ArticleId><ArticleId IdType="pubmed">30215545</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh RSP, Walker GS, Kadar EP, Cox LM, Eng H, Sharma R, et al. Metabolism and excretion of nirmatrelvir in humans using quantitative fluorine nuclear magnetic resonance spectroscopy: a novel approach for accelerating drug development. Clin Pharmacol Ther. 2022;112:1201–6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.2683</ArticleId><ArticleId IdType="pubmed">35678736</ArticleId></ArticleIdList></Reference><Reference><Citation>James AD, Marvalin C, Luneau A, Meissner A, Camenisch G. Comparison of <sup>19</sup>F NMR and <sup>14</sup>C measurements for the assessment of ADME of BYL719 (Alpelisib) in humans. Drug Metab Dispos. 2017;45:900–7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.117.075424</ArticleId><ArticleId IdType="pubmed">28566285</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration: Bioanalytical Method Validation Guidance for Industry. 2018; Available from: https://www.fda.gov/media/70858/download .</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration: Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies. 2022; Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-human-radiolabeled-mass-balance-studies .</Citation></Reference><Reference><Citation>Asakura M, Fukami T, Nakajima M, Fujii H, Atsuda K, Itoh T, et al. Hepatic dipeptidyl peptidase-4 controls pharmacokinetics of vildagliptin in vivo. Drug Metab Dispos. 2017;45:237–45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.116.073866</ArticleId><ArticleId IdType="pubmed">27895112</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong FD, Pang XY, Zhao JH, Deng P, Zheng MY, Zhong DF, et al. Hydrolytic metabolism of cyanopyrrolidine DPP-4 inhibitors mediated by dipeptidyl peptidases. Drug Metab Dispos. 2019;47:238–48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.118.084640</ArticleId><ArticleId IdType="pubmed">30530814</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Zhang ZW, Hang J, Liu J, Guo FS, Ding Y, et al. Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target. Science. 2023;381:501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.add5787</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, Shibasaki M. Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors. Pharmacol Rep. 2009;61:899–908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1734-1140(09)70147-1</ArticleId><ArticleId IdType="pubmed">19904014</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh RSP, Toussi SS, Hackman F, Chan PL, Rao R, Allen R, et al. Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir. Clin Pharmacol Ther. 2022;112:101–11.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>